Why the study?
Does aspirin prevent venous thromboembolism as effectively and safely as low-molecular-weight heparins in patients undergoing elective hip and knee replacement?
Does aspirin prevent venous thromboembolism as effectively and safely as low-molecular-weight heparins in patients undergoing elective hip and knee replacement?
This review argues that NICE guidelines should be revised to include aspirin as a safe, effective, and cost-efficient option for VTE prophylaxis following joint replacement.
No takes yet. Share an insight, caveat, or question.
Should not yet change VTE prophylaxis practice; leaves open confirmation of aspirin's equivalence by RCTs.
Jameson et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: